STABLE results: Warfarin home monitoring achieves excellent INR control

American Journal of Managed Care

Volumn 20, Issue 3, 2014, Pages 202-209

  DeSantis, Grace ^a   Hogan Schlientz, Jackie ^b   Liska, Gary ^b   Kipp, Shari ^b   Sallee, Ramarion ^b   Wurster, Mark ^c   Kupfer, Kenneth ^a   Ansell, Jack ^d  

^a Alere Inc   (United States)

^b Alere Home Monitoring Inc   (United States)

^c Standing Stone Inc   (United States)

^d LENOX HILL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

ADULT; ANTICOAGULATION; ARTICLE; HOME MONITORING; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; POINT OF CARE TESTING; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

EID: 84897396023     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Nutescu E, Bathija S, Sharp L, Gerber BS, Schumock GT, Fitzgibbon ML. Anticoagulation patient self-monitoring in the United States: considerations for clinical practice adoption. Pharmacotherapy. 2011;31 (12):1161-1174.
2. Centers for Medicare & Medicaid Services. Decision memo for prothrombin time (INR) monitor for home anticoagulation management (CAG-00087C, 2001; CAG-00087R, 2008). [memorandum]. Baltimore, MD.
3. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: ACCP Evidence-Based Clinical Practice Guidelines. Chest. 2008;133(6 suppl):160S-198S. (Pubitemid 351892967)
4. Rose A, Berlowitz D, Ash A, Ozonoff A, Hylek EM, Goldhaber-Fiebert JD. The business case for quality improvement: oral anticoagulation for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2011;4(4):416-424.
5. Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis. 2000;9(3):283-292. (Pubitemid 30201262)
6. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy. Chest. 2012;141(2 suppl):e152S-e184S.
7. Heneghan C, Ward A, Perera R, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual data. Lancet. 2012;379(9813):322-334.
8. Bloomfield HE, Krause A, Greer N, et al. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. Ann Intern Med. 2011;154(7):472-482.
9. Gardiner C, Longair I, Pescott M, et al. Self-monitoring of oral anticoagulation: does it work outside trial conditions? J Clin Pathol. 2009; 62(2):168-171.
10. Oral anticoagulation patient self-testing: consensus guidelines for practical implementation. Managed Care. 2008; 17(10, suppl 9):1-8.
11. Ansell J, Jacobson A, Levy J, Voller H, Hasenkam JM. Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation: international consensus guidelines prepared by international self-monitoring association for oral anticoagulation. Int J Cardiol. 2005;99(1):37-45. (Pubitemid 40261022)
12. Association for the Advancement of Medical Instrumentation. Standard HE75: Human factors engineering-design of medical devices. Arlington, VA: 2009.
13. Matchar DB, Jacobson A, Dolor R, et al. Effect of home testing of international normalized ratio on clinical events. N Eng J Med. 2010; 363(17):1608-1620.
14. Rosendaal R, Cannegieter S, van der Meer F, van der Meer F, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236-239. (Pubitemid 23069000)
15. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schunemann JH. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: ACCP Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):7S-47S.
16. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1(2):84-91.
17. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12): 1139-1151.
18. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891.
19. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(10): 981-992.
20. Hylek E, Skates S, Sheehan M, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation. N Eng J Med. 1996;335(8):540-546. (Pubitemid 26272308)
21. Erkens PMG, ten Cate H, Buller HR, Prins MH. Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. PLoS One. 2012;7(9):e42269.
22. Matchar DB. Do anticoagulation management services improve care? implications of the managing anticoagulation services trial. Card Electrophysiol Rev. 2003;7(4):379-381.